Pb_e_steritalc 056e-2.indd

STERITALC®
Large Particle Size Talc
for internal use
Indications
• chronic pleurisies, principally malignant • spontaneous pneumothorax According to the literature, talc is more effi cient than Bleomycine and cyclines1). It appears that talc is the best sclerosis product available and can be used even after the application of other agents has failed.
Features
• produced for medical purposes only (talcum • graded talc perfectly controlled granulometry avoiding any migration as shown by Pr ASTOUL et al.2), Marseilles, France • suitable for all pleurodesis indications, it is non- soluble and induces permanent pleurodesis • compared with Cyclines, STERITALC® is more
effective and less painful. Any pain ocurring can be reduced according to doctor‘s decision, for The dose varies from 3 to 6 grams for malignant example by using Xylocaine 1% in the pleura or in pleural effusion and generally does not exceed 2g for spontaneous pneumothorax. Individual doses • complies with the regulations of the European according to physician’s decision.
Pharmacopoeia (3rd edition): STERITALC® is a phar-
STERITALC® comes in three pharmaceutical forms
maceutical talc of a lamellar structure which is stable and inert physically, chemically and biolo-gically.
• Vial F2, F4
For physicians preferring to use talc in bulk, a line of talc in vials is available, which can be used for slurry as well as talc poudrage.
Description
• Spray (Aerosol)
STERITALC®sterile, 3g of STERITALC® per spray One box contains two pouches each containing one ready to use 3g STERITALC® aerosol and one canula. To be used for talc poudrage procedures.
Extra-long canula (24/box)fi ts only with 16833 • Spray PF4
Safe handling and storage. Unlike the Spray (Aerosol), STERITALC® PF4’s propellant is air. For this reason it is not considered an IATA dangerous sterile, 4 g of STERITALC® in a vial1 vial / pouch, 24 pouches / carton Pulverisation at room temperature: No risk of hypothermia or local necrosis due to extremely Can be used for talc poudrage or slurry.
1) Cf. reverse page for a bibliography.
2) Fraticelli, CHEST 2002; 122:1737-1741 NOVATECH SANew Biotechnology for LifeZ.I. Athélia III - 1058, Voie Antiope F - 13705 LA CIOTAT CEDEX TEL + 33 (0) 442 98 15 60 FAX +33 (0) 442 98 15 63 Bibliography
Antony VB; Loddenkemper R; Astoul P; Boutin C; Kennedy L, Harley RA, Sahn SA, Strange C: Talc
Goldstraw P; Hott J; Rodriguez Panadero F; Sahn SA: Slurry Pleurodesis. Chest 107 (1995): 1707-12
Management of malignant pleural effusions. Euro-
pean respiratory journal 18 (2001): 402-419
Mager HJ; Maesen B; Verzijlbergen F; Schramel F:
Distribution of talc suspension during treatment of
Bloom AI; Wilson MW; Kerlan RK Jr; Gordon RL; La- malignant pleural effusion with talc pleurodesis.
Berge JM: Talc pleurodesis through small-bore per-
cutaneous tubes. Cardiovascular and interventional
radiology 22 (1999): 433-436
Marom EM; Patz EF Jr; Erasmus JJ; McAdams HP;
Goodman PC; Herndon JE: Malignant pleural ef-
Bresticker MA, Oba J, LoCicero J, Greene R; fusions: treatment with small-bore-catheter
Optimal pleurodesis: a comparison study.
thoracostomy and talc pleurodesis. Radiology 210
Annals of Thoracic Surgery 55 (1993): 364-367 Cardillo G; Facciolo F; Carbone L; Regal M; Corzani F; Milanez de Campos JR; Filho LO; de Campos Werebe Ricci A; Di Martino M; Martelli M: Long-term follow-
E; Sette H Jr; Fernandez A; Filomeno LT; Jatene FB: up of video-assisted talc pleurodesis in malignant
Thoracoscopy talc poudrage, a 15 Year experi-
recurrent pleural effusions. European journal of
ence. Chest 119 (2001): 801-806
cardio-thoracic surgery 21 (2002): 302-305 Nasreen N; Mohammed KA; Dowling PA; Ward MJ; Erickson KV; Yost M; Bynoe R; Almond C; Notting- Galffy G; Antony VB: Talc induces apoptosis in hu-
ham J: Primary treatment of malignant pleural
man malignant mesothelioma cells in vitro. Ameri-
effusions: video-assisted thoracoscopic surgery
can journal of respiratory and critical care medicine poudrage versus tube thoracostomy. The American
Sanchez-Armengol A, Rodriguez-Panadero F; Survival
Ferrer J; Montes JF; Villarino MA; Light RW; and talc pleurodesis in metastatic pleural carcino-
García-Valero J: Infl
uence of particle size
ma, revisited. Chest 104 (1993): 1482-1485
on extrapleural talc dissemination after talc
slurry pleurodesis. Chest 122 (2002): 1018-1027
Tschopp JM; Bolliger CT; Boutin C: Treatment of
spontaneous pneumothorax: why not simple talc
Ferrer J; Villarino MA; Tura JM; Traveria A; pleurodesis by medical thoracoscopy. Respiration
Light RW: Talc preparations used for pleurode-
sis vary markedly from one preparation to
another. Chest 119 (2001): 1901-1905
Tschopp JM; Boutin C; Astoul P; Janssen JP; Grandin S; Bolliger CT; Delaunois L; Driesen P; Fraticelli A; Robaglia-Schlupp A; Riera H; Monja- Tassi G; Perruchoud AP: Talcage by medical
nel-Mouterde S; Cau P; Astoul P: Distribution of
thoracoscopy for primary spontaneous pneu-
calibrated talc after intrapleural administration:
mothorax is more cost-effective than
an experimental study in rats. Chest 122 (2002):
drainage: a randomised study. European respiratory
Glazer M; Berkman N; Lafair JS; Kramer MR: Suc-
Viallat JR, Rey F, Astoul P, Boutin C; Thoracoscopic
cessful talc slurry pleurodesis in patients with
talc poudrage pleurodesis for malignant effusions.
nonmalignant pleural effusion. Chest 117 (2000):
Weissberg D, Ben-Zeev I; Talc Pleurodesis. Journal
Keller SM; Current and future therapy for malig-
of Thoracic and Cardiovascular Surgery 106 (1993): nant pleural effusion. Chest 103 (1993): 63S-67S

Source: http://www.medicor.nl/Portals/0/Steritalc-2007.pdf